Lengthy Viral Suppression May Cut Cancer Risk in HIV Infected

Findings strongest for AIDS-defining cancers; no link for non-AIDS defining cancers not caused by viruses

Please note: This article was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. And "More information" links may no longer work. Questions about personal health should always be referred to a physician or other health care professional.

MONDAY, June 11, 2018 (HealthDay News) -- Antiretroviral therapy resulting in long-term viral suppression of HIV may contribute to cancer prevention, according to a study published online June 12 in the Annals of Internal Medicine.

Lesley S. Park, Ph.D., M.P.H., from Stanford University in Palo Alto, Calif., and colleagues assessed data from a large prospective cohort from the Veterans Affairs to determine whether long-term HIV suppression resulting from sustained antiretroviral therapy reduced the incidence of AIDS-defining cancers and non-AIDS-defining cancers (some of which are caused by oncogenic viruses). Participants included 42,441 HIV-positive veterans and 104,712 demographically-matched uninfected veterans (1999 to 2015).

The researchers found that cancer incidence for HIV-positive versus uninfected persons was highest for unsuppressed persons (relative risk [RR], 2.35), lower among persons with early suppression (RR, 1.99), and lowest among persons with long-term suppression (RR, 1.52). This trend was strongest for AIDS-defining cancers (unsuppressed: RR, 22.73; early suppression: RR, 9.48; long-term suppression: RR, 2.22) and much weaker for non-AIDS defining cancers caused by viruses (unsuppressed: RR, 3.82; early suppression: RR, 3.42; long-term suppression: RR, 3.17). No association was seen for non-AIDS defining cancers not caused by viruses.

"Patients with long-term viral suppression still had excess cancer risk," the authors write.

Abstract/Full Text (subscription or payment may be required)

Last Updated: